文献速递心力衰竭与心肌病心律失常

未折叠蛋白反应在PLN R14del心肌病中作为代偿机制及潜在治疗靶点

Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy.
PubMed 文献 · Circulation · 2021-04-30

该研究利用人诱导多能干细胞来源心肌细胞(hiPSC-CM)的单细胞RNA测序,揭示PLN R14del心肌病中未折叠蛋白反应(UPR)通路被诱导激活。抑制UPR三条主要信号分支会加重收缩功能障碍,而用小分子激活UPR可剂量依赖性改善收缩功能,提示UPR具有保护作用且可能成为治疗靶点。

要点

  • PLN R14del hiPSC-CM模型重现了疾病的收缩缺陷,并显示UPR通路激活。
  • 沉默IRE1、ATF6或PERK任一UPR分支均加重PLN R14del hiPSC-CM的收缩功能障碍。
  • BiP诱导剂X激活UPR可剂量依赖性改善2D和3D工程心肌组织的收缩缺陷,且不影响钙稳态。

核心结论

  • UPR在PLN R14del心肌病中发挥保护作用,调控UPR可能成为治疗策略。

研究设计与样本

  • 研究采用单细胞RNA测序分析PLN R14del与同基因对照hiPSC-CM,并使用2维和3维收缩功能测定评估调控疾病相关通路的影响。

主要发现

  • PLN R14del hiPSC-CM与同基因对照相比,UPR通路被诱导;PLN R14del患者心脏中也可见UPR激活。
  • siRNA沉默IRE1、ATF6或PERK任一UPR信号分支均加重PLN R14del hiPSC-CM的收缩功能障碍。
  • BiP诱导剂X处理PLN R14del hiPSC-CM,在2维培养和3维工程心肌组织中均剂量依赖性改善收缩缺陷,且不影响钙稳态。

临床怎么用

  • UPR激活可能作为PLN R14del心肌病的潜在治疗方向,但尚未进入临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phospholamban (PLN) is a critical regulator of calcium cycling and contractility in the heart. The loss of arginine at position 14 in PLN (R14del) is associated with dilated cardiomyopathy with a high prevalence of ventricular arrhythmias. How the R14 deletion causes dilated cardiomyopathy is poorly understood, and there are no disease-specific therapies. METHODS: We used single-cell RNA sequencing to uncover PLN R14del disease mechanisms in human induced pluripotent stem cells (hiPSC-CMs). We used both 2-dimensional and 3-dimensional functional contractility assays to evaluate the impact of modulating disease-relevant pathways in PLN R14del hiPSC-CMs. RESULTS: Modeling of the PLN R14del cardiomyopathy with isogenic pairs of hiPSC-CMs recapitulated the contractile deficit associated with the disease in vitro. Single-cell RNA sequencing revealed the induction of the unfolded protein response (UPR) pathway in PLN R14del compared with isogenic control hiPSC-CMs. The activation of UPR was also evident in the hearts from PLN R14del patients. Silencing of each of the 3 main UPR signaling branches (IRE1, ATF6, or PERK) by siRNA exacerbated the contractile dysfunction of PLN R14del hiPSC-CMs. We explored the therapeutic potential of activating the UPR with a small molecule activator, BiP (binding immunoglobulin protein) inducer X. PLN R14del hiPSC-CMs treated with BiP protein inducer X showed a dose-dependent amelioration of the contractility deficit in both 2-dimensional cultures and 3-dimensional engineered heart tissues without affecting calcium homeostasis. CONCLUSIONS: Together, these findings suggest that the UPR exerts a protective effect in the setting of PLN R14del cardiomyopathy and that modulation of the UPR might be exploited therapeutically.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Feyen DAM, Perea-Gil I, Maas RGC, et al. Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy. Circulation. 2021. PMID: 33928785. doi:10.1161/CIRCULATIONAHA.120.049844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。